SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against certain of its officers and directors for alleged breaches of fiduciary duty.
Shareholders who have held Sarepta shares continuously since prior to June 22, 2023, may have standing to seek corporate governance reforms, the return of funds back to the company, and a court-approved incentive award, all at no cost to them.
What Should Sarepta Shareholders Do?
If you have held Sarepta shares continuously since prior to June 22, 2023, you may have standing to seek corporate governance reforms at Sarepta, including improvements to internal controls, transparency, and executive oversight.
To learn more, visit: https://www.johnsonfistel.com/investigations/sarepta-therapeutics/ or contact Johnson Fistel, PLLP at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
What Is Johnson Fistel Investigating?
A previously filed class action complaint alleges that Sarepta and certain of its executives made materially false and misleading statements, and/or failed to disclose material adverse facts, concerning the safety profile and regulatory and commercial prospects of ELEVIDYS, the Company's gene therapy for Duchenne muscular dystrophy.
According to the complaint, Sarepta allegedly failed to disclose that ELEVIDYS posed significant safety risks to patients and that the Company's trial regimes and protocols failed to detect severe side effects.
The complaint further alleges that serious adverse events associated with ELEVIDYS would cause Sarepta to halt recruitment and dosing in certain trials, attract regulatory scrutiny, and create greater risks concerning the therapy's existing and expanded approvals. When Sarepta disclosed patient deaths associated with acute liver failure following treatment and subsequent safety and regulatory developments, investors allegedly suffered losses.
About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investor Rights:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on U.S. exchanges. For more information about the firm and how we may be able to help you recover your losses, please visit www.johnsonfistel.com.
Achievements:
In 2024, Johnson Fistel was ranked in the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. The firm has recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel, marking the eighth time it has been recognized among the top U.S. plaintiffs' securities law firms.
Attorney Advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Contact:
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq.
(619) 814-4471
jimb@johnsonfistel.com or fjohnson@johnsonfistel.com
